IGF2 genotype and obesity in men and women across the adult age span.

We studied a previously reported association between the IGF2 gene's ApaI polymorphism and obesity in 500 healthy men and women (19-90 y). We hypothesized that individuals homozygous for the IGF2 A allele (A/A) would exhibit lower body mass, BMI and DEXA-measured fat mass compared to G/G homozygotes. Subjects were categorized as exhibiting the G/G (n = 241), G/A (n = 197) or A/A (n = 62) genotype. Contrary to our hypothesis, no difference was observed in body mass, body mass index (BMI) or fat mass between the G/G and A/A genotype groups in the entire cohort. Surprisingly, Caucasian A/A individuals (n = 427) exhibited significantly higher fat mass compared to Caucasian G/G individuals (P < 0.05). In summary, individuals homozygous for the IGF2 G allele do not exhibit higher body mass, BMI or fat mass compared to A/A individuals; however, Caucasians with the A/A genotype exhibit higher fat mass than G/G individuals.

Relationship between muscle strength and the time taken to complete a standardized walk-turn-walk test.

We examined the effects of age and gender on the relationship between knee strength and walking time during a walk-turn-walk test in 176 male and 168 female generally healthy participants of the Baltimore Longitudinal Study of Aging who were aged 21-89 years. Subjects were timed as they walked 50 ft (15.24 m), turned around, and walked back to the starting point, both at a comfortable pace and as fast as possible. Isokinetic concentric knee extensor strength was measured at 30 degrees /s by using a Kin-Com dynamometer. Both comfortable and fast gait times increased with increasing age for both women and men, starting in middle age. An interaction was found between gender and age showing that older women are slower than older men at both paces. Gait time decreased linearly with increasing knee extensor strength, plateauing at higher strength levels (>130 N m for comfortable gait, and 190 N m for fast gait). Most women occupied the linear part of the curve below the plateau. Adjustment for body size, age, physical activity, and particularly number of steps to complete the task removed the relationship between strength and gait time for the comfortable gait. Women took longer to complete the walk-turn-walk test than men at older ages, were on the linear part of the strength-gait time relationship, and used more steps to complete the task, all of which may contribute to their greater likelihood of frailty in later years.

CNTF genotype is associated with muscular strength and quality in humans across the adult age span.

The relationship between ciliary neurotrophic factor (CNTF) genotype and muscle strength was examined in 494 healthy men and women across the entire adult age span (20-90 yr). Concentric (Con) and eccentric (Ecc) peak torque were assessed using a Kin-Com isokinetic dynamometer for the knee extensors (KE) and knee flexors (KF) at slow (0.52 rad/s) and faster (3.14 rad/s) velocities. The results were covaried for age, gender, and body mass or fat-free mass (FFM). Individuals heterozygous for the CNTF null (A allele) mutation (G/A) exhibited significantly higher Con peak torque of the KE and KF at 3.14 rad/s than G/G homozygotes when age, gender, and body mass were covaried (P < 0.05). When the dominant leg FFM (estimated muscle mass) was used in place of body mass as a covariate, Con peak torque of the KE at 3.14 rad/s was also significantly greater in the G/A individuals (P < 0.05). In addition, muscle quality of the KE (peak torque at 3.14 rad x s(-1) x leg muscle mass(-1)) was significantly greater in the G/A heterozygotes (P < 0.05). Similar results were seen in a subanalysis of subjects 60 yr and older, as well as in Caucasian subjects. In contrast, A/A homozygotes demonstrated significantly lower Ecc peak torque at 0.52 rad/s for both KE and KF compared with G/G and G/A groups (P < 0.05). No significant relationships were observed at 0.52 rad/s between genotype and Con peak torque. These data indicate that individuals exhibiting the G/A genotype possess significantly greater muscular strength and muscle quality at relatively fast contraction speeds than do G/G individuals. Because of high positive correlations between fast-velocity peak torque and muscular power, these findings suggest that further investigations should address the relationship between CNTF genotype and muscular power.

Fatigue effects on motor unit activity during submaximal contractions.

OBJECTIVE: To examine motor unit changes during the development of fatigue in healthy subjects. DESIGN: Automated decomposition-enhanced spike-triggered averaging was used to characterize motor unit size and firing rate in the dominant vastus medialis during maintained contractions at 10% and 30% of maxima voluntary contraction (MVC). SETTING: Academic outpatient neuromuscular clinic. PARTICIPANTS: Healthy laboratory personnel. MAIN OUTCOME MEASURES: Surface electromyogram, surface-detected motor unit action potential amplitude (S-MUAP), mean firing rate, force (MVC), motor unit index. RESULTS: Surface electromyogram values and S-MUAP amplitudes increased during both 10% and 30% MVC fatiguing contractions, while mean firing rates decreased. A motor unit index, indicating the degree of motor unit pool activation, increased similarly to S-MUAP size, implying that new and larger units were recruited to maintain the contraction. Repeated contractions led to earlier motor unit changes and fatigue. CONCLUSION: During submaximal fatiguing contractions, additional motor units are activated to maintain strength. These changes begin early, within the first minute, particularly after a previous fatiguing effort.

The bloodless lactate profile.

The blood lactate profile (HLa-P) is an accepted method of evaluating athletes and providing a basis for the prescription of training intensity. For both logistic and public health reasons HLa-P is less than optimal. In this study we evaluate the relative velocity or the %HR-max, obtained during a training session, as alternatives to HLa-P. Competitive speed skaters (N = 20) performed HLa-P consisting of 5.2000 m/400 m at incremental velocities ranging from very slow to maximal (time = 3.0-5.0 min). Blood lactate measured during a 60-s interval following each repetition was used to construct HLa-P and to predict the velocity associated with steady state (HLa = 4.0-6.5 mmol.l-1). Relative velocity was calculated relative to the velocity of the maximal trial. A plot of relative velocity and %HRmax vs HLa demonstrated that HLa = 4.0-6.5 mmol.l-1 occurred at a relative velocity of 78-88% (R2 = 0.807) and at 84-92 %HRmax (R2 = 0.748). In a separate training session the relative velocity and %HRmax models were cross validated by having the subjects skate 9.2000 m/400 m at constant velocity. HLa changes during the training session defined the presence/absence of steady state (delta HLa < 1.0 mM from trial 3 to 9). Comparing the velocity during the training session vs the velocity predicted from HLa-P, relative velocity model and %HRmax model allowed a test of the accuracy of bloodless means of defining steady state. HLa-P correctly predicted 81% of training session HLa responses, the relative velocity model correctly predicted 78%, and the %HRmax model correctly predicted 68%.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of specific versus cross-training on running performance.

The cross-training (XT) hypothesis suggests that despite the principle of specificity of training, athletes may improve performance in one mode of exercise by training using another mode. To test this hypothesis we studied 30 well-trained individuals (10 men, 20 women) in a randomized longitudinal trail. Subjects were evaluated before and after 8 weeks of enhanced training (+10%/week), accomplished by adding either running (R) or swimming (XT) to baseline running, versus continued baseline running (C). Both R (-26.4s) and XT (-13.2s) improved time trial (3.2 km) performance, whereas C did not (-5.4s). There were no significant changes during treadmill running in maximum oxygen uptake (VO2peak; -0.2, -6.0, and +2.7%), steady state submaximal VO2 at 2.68 m.s-1 (-1.2, -3.3 and +0.2 ml.kg-1.min-1), velocity at VO2peak (+0.05, +0.25 and +0.09 m.s-1) or accumulated O2 deficit (+11.2, -6.1 and +9.4%) in the R, XT or C groups, respectively. There was a significant increase in velocity associated with a blood lactate concentration of 4 mmol.l-1 in R but not in XT or C (+0.32, +0.07 and +0.08 m.s-1). There were significant changes in arm crank VO2peak (+5%) and arm crank VO2 at 4 mmol.l-1 (+6.4%) in XT. There was no significant changes in arm crank VO2peak (+1.3 and -7.7%) or arm crank VO2 at 4 mmol.l-1 (+0.8 and +0.4%) in R or C, respectively. The data suggest that muscularly non-similar XT may contribute to improved running performance but not to the same degree as increased specific training.

Fixed time versus fixed distance protocols for the blood lactate profile in athletes.

Laboratory studies of blood lactate accumulation often use a fixed time protocol to define the onset (4 mM) of blood lactate accumulation (OBLA) or other indices of blood lactate concentration. For practical reasons, field studies with athletes often use a fixed distance protocol to accomplish the same goal. Whether these variations of protocol are comparable has not been established. We studied 10 subjects in the laboratory during fixed time (4 minute) and fixed distance (2 km) exercise protocols on a racing bicycle attached to a wind load simulator. The fixed distance studies required 3-6 minutes to complete. We also studied the subjects during fixed distance (2 km) rides in the field. In the laboratory there were no systematic differences in the velocity (34.3 4.6 vs 34.2 +/- 4.6 km.hr-1), VO2 (2.78 +/- 0.60 vs 2.84 +/- 0.62 liters.min-1), or heart rate (159 +/- 16 vs 155 +/- 14 beats.min-1) at OBLA in the fixed time vs fixed distance protocols. The correlation coefficients for velocity (r = 0.97), VO2 (r = 0.97) and heart rate (r = 0.94) further indicate the similarity of results. In the field study there was a significant difference in velocity (29.9 +/- 4.8 vs 34.2 +/- 4.6 km.hr-1) but not heart rate (155 +/- 18 vs 155 +/- 15 beats.min-1) at OBLA versus the fixed distance laboratory study. The correlations for velocity (r = 0.47) and heart rate (r = 0.93) support these data. The results suggest that the practical modification of the lactate profile technique of using fixed distance versus fixed time exercise stages does not systematically influence the outcome, at least for exercise stage durations approximating 4 minutes.

Effect of pacing strategy on cycle time trial performance.

Despite interest in competitive strategy by coaches and athletes, there are no systematically collected data regarding the effect of differences in pacing strategy on the outcome of middle distance (2-4 min duration) events. In this study different pacing strategies were evaluated using a 2-km time trial on a bicycle attached to a wind load simulator. Well-trained subjects (N = 9) performed five separate time trials with the pace during the first 50% of the trial experimentally constrained within the usual real world range from very slow (approximately 55% of best time) to very fast (approximately 48% of best time). Serial VO2 was measured to estimate the oxidative contributions to the trial and accumulated O2 deficit and postexercise blood lactate measured to estimate the anaerobic contribution to the trial. The evenly paced trial (first 1 km = 50.9% final time) produced the fastest total time. The starting pace to final time relationship was described by a U shaped second order polynomial curve with the nadir for final time at a starting pace of 51% of best total time. There were no systematic differences in serial VO2, accumulated O2 deficit, or postexercise lactate that could account for the pacing related variations in performance. The data support the concept of relatively even pacing in middle distance events with negative consequences for even small variations in this strategy.

Pathways of complement activation in chronic discoid lupus: serologic and immunofluorescence studies.

To assess the relative roles of the classic and alternative pathways of complement activation in chronic discoid lupus erythematosus (CDLE), serum levels of properdin, C3, and C4, and deposition of these proteins in the dermal-epidermal junction (DEJ) of 20 CDLE patients were compared to the findings in patients with clinically active and inactive SLE. Properdin was demonstrated in the DEJ of 10 of 14 (71%) histologically typical skin lesions from patients with CDLE, usually in association with deposits of immunoglobulin, C3, and C4. Properdin levels in CDLE patients were significantly increased (137 +/- 34%) (P less than 0.05) when compared to normal controls (101 +/- 18%) or to patients with clinically active SLE (89 +/- 32%). C3, C4, DNA-binding, and antinuclear antibody tests in CDLE were indistinguishable from those in normals, but significantly different from patients with active SLE (P less than 0.05). The complement profiles of patients with clinically inactive SLE resembled those of CDLE patients more closely than those of active SLE patients.

Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus.

61 biopsies of normal skin from the deltoid area and lesional skin from various sites from 48 patients with systemic lupus erythematosus (SLE) were studied for the presence of properdin, C3, C4, and immunoglobulins (IgG, IgM, and IgA) in the dermal-epidermal junction (DEJ) using direct and indirect immunofluorescence. Properdin was present in 50% of normal and 40% of lesional skins. Properdin was present without C4 in only 2 of 38 nonlesional skin biopsies and in only 2 of 20 lesions. There was no significant difference in incidence of deposition of any of the six proteins studied between nonlesional and lesional skin. The frequency of deposition of each of the proteins correlated with clinical disease activity. The presence of proteins in the DEJ did not correlate with the presence of active renal disease at the time of biopsy nor with previously documented active nephritis. In addition, no other single clinical manifestation correlated with the presence of DEJ deposition of any protein studied. IgA was not demonstrated in the DEJ of nonlesional skin of 16 patients in remission and was present in 7 of 23 patients with active disease (P less than 0.05). Deposition of properdin in lesional skin correlated with the presence of extracutaneous disease activity (P less than 0.05). Analysis of serologic studies on serum obtained at the time of biopsy revealed a statistically significant correlation between C4 and C3 (r = 0.67). This correlation was stronger than that between properdin and C4 (r = 0.37). Titer of antinuclear antibody and percent of DNA binding correlated better with C4 levels than with properdin levels. Serum properdin levels were significantly lower in patients with active disease than in those in remission (P less than 0.05). Serum properdin levels were significantly lower in patients with properdin deposits in lesional skin than in those without properdin deposits. The data suggest that both alternative and classical pathways are activated in patients with clinically active SLE.